Intrastriatal botulinum toxin abolishes pathologic rotational behaviour and induces axonal varicosities in the 6-OHDA rat model of Parkinson's disease

Neurobiology of Disease

Volumn 41, Issue 2, 2011, Pages 291-298

  Wree, Andreas ^a   Mix, Eilhard ^a   Hawlitschka, Alexander ^a   Antipova, Veronica ^a   Witt, Martin ^a,b   Schmitt, Oliver ^a   Benecke, Reiner ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

6 Hydroxy dopamine; Apomorphine induced rotation; Axonal varicosities; Botulinum neurotoxin A; Motor function; Striatum

Indexed keywords

BOTULINUM TOXIN A; CHOLINE ACETYLTRANSFERASE; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FOREBRAIN; IMAGE ANALYSIS; IMMUNOELECTRON MICROSCOPY; IMMUNOHISTOCHEMISTRY; MALE; MEDIAL FOREBRAIN BUNDLE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SENSORIMOTOR FUNCTION;

ANIMALS; AXONS; BOTULINUM TOXINS, TYPE A; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DYSKINESIAS; GROWTH CONES; MALE; NERVE REGENERATION; NEUROTOXINS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; ROTATION;

EID: 78650588622     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.09.017     Document Type: Article

References (36)

1. Antonucci F., Rossi C., Gianfranceschi L., Rossetto O., Caleo M. Long-distance retrograde effects of botulinum neurotoxin A. J. Neurosci. 2008, 28:3689-3696.
2. Ashton A.C., Dolly J.O. Characterization of the inhibitory action of botulinum neurotoxin type A on the release of several transmitters from rat cerebrocortical synaptosomes. J. Neurochem. 1988, 50:1808-1816.
3. Benecke R., Dressler D. Botulinum toxin treatment of axial and cervical dystonia. Disabil. Rehabil. 2007, 29:1769-1777.
4. Bigalke H., Heller I., Bizzini B., Habermann E. Tetanus toxin and botulinum A toxin inhibit release and uptake of various transmitters, as studied with particulate preparations from rat brain and spinal cord. Naunyn Schmiedebergs Arch. Pharmacol. 1981, 316:244-251.
5. Bigalke H., Dreyer F., Bergey G. Botulinum A neurotoxin inhibits non-cholinergic synaptic transmission in mouse spinal cord neurons in culture. Brain Res. 1985, 360:318-324.
6. Borodic G., Johnson E., Goodnough M., Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 1996, 46:26-29.
7. Brunger A.T., Rongsheng J., Breidenbach M.A. Interactions between botulinum neurotoxins and synaptic vesicle proteins. Botulinum Toxin. Therapeutic Clinical Practice and Science 2009, 41-52. Saunders Elsevier, Philadelphia. J. Jankovic, A. Albanese, M.Z. Atassi, J.O. Dolly, M. Hallett, N.H. Mayer (Eds.).
8. Day M., Wang Z., Ding J., An X., Ingham C.A., Shering A.F., Wokosin D., Ilijic E., Sun Z., Sampson A.R., Mugnaini E., Deutch A.Y., Sesack S.R., Arbuthnott G.W., Surmeier D.J. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat. Neurosci. 2006, 9:251-259.
9. de Paiva A., Meunier F.A., Molgó J., Aoki K.R., Dolly J.O. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc. Natl Acad. Sci. USA 1999, 96:3200-3205.
10. de Paola V., Holtmaat A., Knott G., Song S., Wilbrecht L., Caroni P., Svoboda K. Cell type-specific structural plasticity of axonal branches and boutons in the adult neocortex. Neuron 2006, 49:861-875.
11. Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., Chapman E.R. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312:592-596.
12. Duvoisin R.C. Cholinergic-anticholinergic antagonism in parkinsonism. Arch. Neurol. 1967, 17:124-136.
13. Ekdawi M.Y., Fowke R. A controlled trial of anti-Parkinson drugs in drug-induced Parkinsonism. Br. J. Psychiatry 1966, 112:633-666.
14. Emerich D.F., Lindner M.D., Winn S.R., Chen E.Y., Frydel B.R., Kordower J.H. Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J. Neurosci. 1996, 16:5168-5181.
15. Heckmann M., Plewig G., Group Hyperhidrosis Study Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study. Arch. Dermatol. 2005, 141:1255-1259.
16. Kaasinen V., Ruottinen H.M., Någren K., Lehikoinen P., Oikonen V., Rinne J.O. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone. J. Nucl. Med. 2000, 41:65-70.
17. Kaplan H.A., Machover S., Rabiner A. A study of the effectiveness of drug therapy in parkinsonism. J. Nerv. Ment. Dis. 1954, 119:398-411.
18. Mahrhold S., Rummel A., Bigalke H., Davletov B., Binz T. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 2006, 580:2011-2014.
19. Mamo D.C., Sweet R.A., Keshavan M.S. Managing antipsychotic-induced parkinsonism. Drug Saf. 1999, 20:269-275.
20. Meredith G.E., Sonsalla P.K., Chesselet M.F. Animal models of Parkinson's disease progression. Acta Neuropathol. 2008, 115:385-398.
21. Mikula G., Jaroszewicz Z., Kolodziejczyk A., Petelczyc K., Sypek M. Imaging with extended focal depth by means of lenses with radial and angular modulation. Opt. Express 2007, 15:9184-9193.
22. Nikkhah G., Bentlage C., Cunningham M.G., Björklund A. Intranigral fetal dopamine grafts induce behavioral compensation in the rat Parkinson model. J. Neurosci. 1994, 14:3449-3461.
23. Norman A.B., Calderon S.F., Giordano M., Sanberg P.R. A novel rotational behaviour model for assessing the restructuring of striatal dopamine effector systems: are transplants sensitive to peripherally acting drugs?. Prog. Brain Res. 1988, 78:61-67.
24. Obeso J.A., Rodríguez-Oroz M.C., Benitez-Temino B., Blesa F.J., Guridi J., Marin C., Rodriguez M. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. Mov. Disord. 2008, 23(Suppl 3):S548-S559.
25. Ordenstein, L., 1868. Sur la paralysie agitante et lasclérose en plaque géneralisée. Thèse de Paris. Delahaye, Paris.
26. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2007, Academic Press, San Diego. sixth ed.
27. Pearce L.B., First E.R., MacCallum R.D., Gupta A. Pharmacologic characterization of botulinum toxin for basic science and medicine. Toxicon 1997, 35:1373-1412.
28. Pisani A., Bernardi G., Ding J., Surmeier D.J. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci. 2007, 30:545-553.
29. Reid S.M., Johnstone B.R., Westbury C., Rawicki B., Reddihough D.S. Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders. Dev. Med. Child Neurol. 2008, 50:123-128.
30. Rogawski M.A. Convection-enhanced delivery in the treatment of epilepsy. Neurotherapeutics 2009, 6:344-351.
31. Schallert T., Tillerson J.L. Intervention strategies for degeneration of dopamine neurons in parkinsonism. Optimizing behavioural assessment of outcome. Central Nervous System Diseases: Innovative Animal Models from Lab to Clinic 2000, 131-151. Humana Press, Totowa, N.J. D.F. Emerich, R.L. Dean, P.R. Sandberg (Eds.).
32. Schallert T., Whishaw I.Q., Ramirez V.D., Teitelbaum P. Compulsive, abnormal walking caused by anticholinergics in akinetic, 6-hydroxydopamine-treated rats. Science 1978, 199:1461-1463.
33. Schallert T., De Ryck M., Whishaw I.Q., Ramirez V.D., Teitelbaum P. Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism. Exp. Neurol. 1979, 64:33-43.
34. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 1970, 24:485-493.
35. Ungerstedt U., Butcher L.L., Butcher S.G., Andén N.E., Fuxe K. Direct chemical stimulation of dopaminergic mechanisms in the neostriatum of the rat. Brain Res. 1969, 14:461-471.
36. Whitney C.M. Medications for Parkinson's disease. Neurologist 2007, 13:387-388.